ciprofloxacin has been researched along with 2019 Novel Coronavirus Disease in 9 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We aimed to determine the noninferiority of fosfomycin compared to ciprofloxacin as an oral step-down treatment for Escherichia coli febrile urinary tract infections (fUTIs) in women." | 9.51 | Fosfomycin Vs Ciprofloxacin as Oral Step-Down Treatment for Escherichia coli Febrile Urinary Tract Infections in Women: A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. ( Bonten, MJM; Branger, J; Geerlings, SE; Hassing, RJ; Hoepelman, AIM; Ketels, T; Koldewijn, EL; Koster, A; Kuiper, S; Ten Doesschate, T; van den Bijllaardt, W; van der Bij, AK; van Mens, SP; van Nieuwkoop, C; van Werkhoven, CH, 2022) |
| "The current study was designed to evaluate camphor neuroprotective role against rats' ciprofloxacin-induced depression." | 8.02 | Neuroprotective role of camphor against ciprofloxacin induced depression in rats: modulation of Nrf-2 and TLR4. ( Kandeil, MA; Khalaf, MM; Mahmoud, HA; Salama, A, 2021) |
| "This study aimed to evaluate the safety and tolerability of a fixed-dose co-formulation of ciprofloxacin and celecoxib (PrimeC) in patients with amyotrophic lateral sclerosis (ALS), and to examine its effects on disease progression and ALS-related biomarkers." | 5.69 | Combination of ciprofloxacin/celecoxib as a novel therapeutic strategy for ALS. ( Abramovich, B; Beaulieu, D; Berry, JD; Birman, N; Drory, VE; Eitan, E; Elgrart, K; Ennist, DL; Paganoni, S; Pushett, A; Russek-Blum, N; Salomon-Zimri, S; Shefner, JM; Van Eijk, RPA, 2023) |
| "We aimed to determine the noninferiority of fosfomycin compared to ciprofloxacin as an oral step-down treatment for Escherichia coli febrile urinary tract infections (fUTIs) in women." | 5.51 | Fosfomycin Vs Ciprofloxacin as Oral Step-Down Treatment for Escherichia coli Febrile Urinary Tract Infections in Women: A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. ( Bonten, MJM; Branger, J; Geerlings, SE; Hassing, RJ; Hoepelman, AIM; Ketels, T; Koldewijn, EL; Koster, A; Kuiper, S; Ten Doesschate, T; van den Bijllaardt, W; van der Bij, AK; van Mens, SP; van Nieuwkoop, C; van Werkhoven, CH, 2022) |
| "In this two-centre randomised clinical trial, critically ill patients with sepsis or septic shock were randomised to AutoKinetics dosing or standard dosing for four antibiotics: vancomycin, ciprofloxacin, meropenem, and ceftriaxone." | 5.51 | Right dose, right now: bedside, real-time, data-driven, and personalised antibiotic dosing in critically ill patients with sepsis or septic shock-a two-centre randomised clinical trial. ( Bosman, RJ; de Grooth, HJ; Driessen, R; Elbers, PWG; Fleuren, LM; Girbes, ARJ; Guo, T; Mathot, RAA; Roggeveen, LF; Swart, EL; Thoral, P; van den Bogaard, B; van Hest, RM, 2022) |
| "The current study was designed to evaluate camphor neuroprotective role against rats' ciprofloxacin-induced depression." | 4.02 | Neuroprotective role of camphor against ciprofloxacin induced depression in rats: modulation of Nrf-2 and TLR4. ( Kandeil, MA; Khalaf, MM; Mahmoud, HA; Salama, A, 2021) |
| " The management of this emergency sanitary situation could not take care of the possible indirect adverse effects on the environment, such as the release of a large amount of pharmaceuticals from wastewater treatment plants." | 1.72 | Suspect screening of wastewaters to trace anti-COVID-19 drugs: Potential adverse effects on aquatic environment. ( Bettinetti, R; Cappelli, F; Fochi, I; Longoni, O; Palumbo, MT; Polesello, S; Rigato, J; Roscioli, C; Rusconi, M; Sala, A; Salerno, F; Stefani, F; Valsecchi, S, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 9 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Donmez, F | 1 |
| Dogan, A | 1 |
| Ten Doesschate, T | 1 |
| Kuiper, S | 1 |
| van Nieuwkoop, C | 1 |
| Hassing, RJ | 1 |
| Ketels, T | 1 |
| van Mens, SP | 1 |
| van den Bijllaardt, W | 1 |
| van der Bij, AK | 1 |
| Geerlings, SE | 1 |
| Koster, A | 1 |
| Koldewijn, EL | 1 |
| Branger, J | 1 |
| Hoepelman, AIM | 1 |
| van Werkhoven, CH | 1 |
| Bonten, MJM | 1 |
| Cappelli, F | 1 |
| Longoni, O | 1 |
| Rigato, J | 1 |
| Rusconi, M | 1 |
| Sala, A | 1 |
| Fochi, I | 1 |
| Palumbo, MT | 1 |
| Polesello, S | 1 |
| Roscioli, C | 1 |
| Salerno, F | 1 |
| Stefani, F | 1 |
| Bettinetti, R | 1 |
| Valsecchi, S | 1 |
| Solaun, O | 1 |
| Rodríguez, JG | 1 |
| Borja, Á | 1 |
| López-García, E | 1 |
| Zonja, B | 1 |
| Postigo, C | 1 |
| Barceló, D | 1 |
| de Alda, ML | 1 |
| Larreta, J | 1 |
| Roggeveen, LF | 1 |
| Guo, T | 1 |
| Fleuren, LM | 1 |
| Driessen, R | 1 |
| Thoral, P | 1 |
| van Hest, RM | 1 |
| Mathot, RAA | 1 |
| Swart, EL | 1 |
| de Grooth, HJ | 1 |
| van den Bogaard, B | 1 |
| Girbes, ARJ | 1 |
| Bosman, RJ | 1 |
| Elbers, PWG | 1 |
| Salomon-Zimri, S | 1 |
| Pushett, A | 1 |
| Russek-Blum, N | 1 |
| Van Eijk, RPA | 1 |
| Birman, N | 1 |
| Abramovich, B | 1 |
| Eitan, E | 1 |
| Elgrart, K | 1 |
| Beaulieu, D | 1 |
| Ennist, DL | 1 |
| Berry, JD | 1 |
| Paganoni, S | 1 |
| Shefner, JM | 1 |
| Drory, VE | 1 |
| Chaves, MJS | 1 |
| Kulzer, J | 1 |
| Pujol de Lima, PDR | 1 |
| Barbosa, SC | 1 |
| Primel, EG | 1 |
| Marciniec, K | 1 |
| Beberok, A | 1 |
| Pęcak, P | 1 |
| Boryczka, S | 1 |
| Wrześniok, D | 1 |
| Salama, A | 1 |
| Mahmoud, HA | 1 |
| Kandeil, MA | 1 |
| Khalaf, MM | 1 |
1 review available for ciprofloxacin and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Updated knowledge, partitioning and ecological risk of pharmaceuticals and personal care products in global aquatic environments.
Topics: Aquatic Organisms; Ciprofloxacin; Cosmetics; COVID-19; Environmental Monitoring; Humans; Pharmaceuti | 2022 |
3 trials available for ciprofloxacin and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Fosfomycin Vs Ciprofloxacin as Oral Step-Down Treatment for Escherichia coli Febrile Urinary Tract Infections in Women: A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial.
Topics: Adult; Anti-Bacterial Agents; Ciprofloxacin; COVID-19; Double-Blind Method; Escherichia coli; Escher | 2022 |
Right dose, right now: bedside, real-time, data-driven, and personalised antibiotic dosing in critically ill patients with sepsis or septic shock-a two-centre randomised clinical trial.
Topics: Adult; Anti-Bacterial Agents; Ciprofloxacin; COVID-19; Critical Illness; Humans; Pandemics; Sepsis; | 2022 |
Combination of ciprofloxacin/celecoxib as a novel therapeutic strategy for ALS.
Topics: Amyotrophic Lateral Sclerosis; Biomarkers; Celecoxib; Ciprofloxacin; COVID-19; Disease Progression; | 2023 |
5 other studies available for ciprofloxacin and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Investigation of the effects of three different generations of fluoroquinolone derivatives on antioxidant and immunotoxic enzyme levels in different rat tissues.
Topics: Adenosine Deaminase; Animals; Antioxidants; Aspartate Aminotransferases; Catalase; Ciprofloxacin; CO | 2022 |
Suspect screening of wastewaters to trace anti-COVID-19 drugs: Potential adverse effects on aquatic environment.
Topics: Azithromycin; Ciprofloxacin; COVID-19; COVID-19 Drug Treatment; Ecosystem; Environmental Monitoring; | 2022 |
Antibiotics in the Basque coast (N Spain): Occurrence in waste and receiving waters, and risk assessment (2017-2020).
Topics: Anti-Bacterial Agents; Azithromycin; Ciprofloxacin; Clarithromycin; COVID-19; Ecosystem; Environment | 2022 |
Ciprofloxacin and moxifloxacin could interact with SARS-CoV-2 protease: preliminary in silico analysis.
Topics: Antiviral Agents; Binding Sites; Chloroquine; Ciprofloxacin; Coronavirus 3C Proteases; COVID-19; COV | 2020 |
Neuroprotective role of camphor against ciprofloxacin induced depression in rats: modulation of Nrf-2 and TLR4.
Topics: Animals; Camphor; Ciprofloxacin; COVID-19; COVID-19 Drug Treatment; Depression; Male; Neuroprotectiv | 2021 |